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STANDARDIZATION FOR SPECIMEN
HANDLING AND PATHOLOGIC
REPORT ON MARGIN FOR
PANCREATICODUODENECTOMY
Kee-Taek Jang
Samsung Medical Center, Sungkyunkwan University,
Korea
Pancreatic cancer showed a very dismal prognosis with
a 5-year survival rate of less than 5%. Most patients
were already inoperable or unresectable status at the
time of diagnosis. The only curable treatment option is
a curative surgical resection with negative resection
margins. The importance of R0 resection (grossly and
microscopically negative margins) is more prominent in
pancreatic cancer surgery than other gastrointestinal
organ malignancy. In pancreatic cancer, the pathologic
evaluation of retroperitoneal margin is more important
for estimation of R0 resection than other anatomical
margin, such as pancreatic neck margin. Reported posi-
tive rates for retroperitoneal margin of pancreatic head
cancer range from 17% to 85% according to research-
ers. This wide range of positive margin rates is due to
the lack of consensus about the definition of positive
retroperitoneal margins for pancreatic head cancer.
Some studies insisted that positive margin can be
defined as the presence of tumor cells at less than one
millimeter from resection margins not the presence of
tumor cells at the margins and strict definition of R1
well discriminates the prognosis of patients with pan-
creatic head cancers. However, there is no pathologic
standard gross protocol for evaluation of retroperito-
neal margin of pancreatic ductal adenocarcinoma. We
studied a standardized gross examination protocol for
specimen handling of pancreaticoduodenectomy and
investigated clinicopathologic parameters. Detailed clin-
icopathologic data were reviewed for cohort of 52
patients with a diagnosis of pancreatic ductal adenocar-
cinoma who underwent pancreaticoduodenectomy with
curative intent at Samsung Medical Center, Seoul,
Korea between July 2012 and April 2013. Exclusion
criteria included macroscopic residual tumor (R2 resec-
tion), requiring the total pancreatectomy and ductal
adenocrcinomas arising from intraductal papillary
mucinous neoplasm. Finally, forty-five patients were
analyzed in the present study. All patients underwent a
standard lymphadenectomy including hepatoduodenal
ligament and the right side of the celiac trunk. If the
invasion of portomesenteric veins was suspected intra-
operatively, en-bloc resection of portomesenteric vein
with reconstruction was carried out. The surgeons
indicated the SMA margins in the operative room by
suturing the inferior and superior SMA margins respec-
tively. And in cases of en-bloc portomesenteric vein
resection, attached veins were indicated by same meth-
ods. All the specimens were delivered to the department
of pathology and fixed overnight in formalin with ret-
roperitoneal side up position, the retroperitoneal side
margin were compartmented into SMA margin, portal
groove margin, and pancreatic neck margin by three
different colors. After color marking, the specimen was
sliced obliquely to the axial plane of the specimen.
Pathologist measured the distance from most front
tumor cells to SMA, portal groove and pancreatic neck
margin, respectively. In cases of portomesenteric vein
resection, presence of venous invasion and venous mar-
gin status were reported and portal groove margin did
not checked. Bile duct margin and both duodenal mar-
gins as well as above three margins were also evaluated.
If any margins had the presence of tumor cells within 1
mm from margins, pathologist reported as ‘revised R1’.
Present series group consisted of 29 men (64.4%) and
16 women (35.6%) with median age of 63 years
(Range, 44–88). Eleven patients (24.4%) of total 45
patients underwent en-bloc portomesenteric vein resec-
tion with reconstruction. All patients showed a patho-
logic T3 classification and thirty-four patients (75.6%)
had a N1 status. Perineural invasion and lymphovascu-
lar invasion were identified in 97.8% and 77.8% of
total tumors respectively. Eight patients (17.8%) had
poorly differentiated tumors. In the present series, eight
patients (17.8%) had the presence of tumor cells at any
margins (classic R1) and twenty-six patients (57.8%)
had the presence of tumor cells within 1 mm from any
margins. Consequently, rate of revised R1 in the pres-
ent series was 75.6%. Compared with classic R1 rate
(5.3%) in the previous series group, there was a signifi-
cant difference (p < 0.001). And classic R1 rate
between two groups was significantly different (24.4%
vs. 5.3%, p < 0.001). The involvement of pancreatic
neck margin (safety margin ≤1 mm) was observed in 0
patients (0%). And the involvement of portal groove
margins and SMA margins were observed in 20
patients (58.8%) and 22 patients (47.8%) respectively.
Four patients (8.9%) of total 45 patients had the
involvement of both margins. In the revised R1 group,
half of patients had radiologic invasion of the portal
vein and there was a no significant difference compared
with revised R0 group. The 23.5% of revised R1 group
underwent portomesenteric vein resection with recon-
struction. In revised R1 groups, 5 patients (14.7%)
were treated with preoperative chemo-concurrent radio-
therapy. And presence of jaundice, histologic grade,
bile duct invasion, duodenal invasion, and nodal
metastasis had no significant differences between two
groups. Only more than 2.5 cm of tumor size had mar-
ginal significance between two groups (p = 0.053). The
present study revealed that rate of revised R1 with
standardized protocol was 75.6% and this result is
comparable to the rates of previous studies. However,
the proportion of 2 or more involved margin in the
present study is only 8.9% compared with two studies
(32% and 45%, respectively). Poor tumor differentia-
tion, large tumor size, and the tumor requiring the
portomesenteric vein resection were associated with R1
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resections. This present study failed to reveal the pre-
dictive factors of R1 resection. However, tumor size of
more than 2.5 cm may be associated with R1 resection.
Because of a relatively small number of cohorts, tumor
differentiation and port mesenteric vein resection had
not statistical significances. In conclusion, we report
that most pancreatic head cancers have a narrow mar-
gin clearance of less than 1 mm with the standardized
protocol. So, we suggest that a standardized gross
examination protocol for pancreatic head cancer speci-
mens should be necessary to generate the comparable
data from different institutes.
Up04
IG G4-RELATED SCLEROSING
CHOLANGITIS
Jong-Kyun Lee
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: Immunoglobulin G4 related disease
(IgG4-RD) is a newly recognized fibroinflammatory
condition characterized by distinguishing clinical, path-
ologic and serologic features. IgG4-RD has been
described in various organs: biliary tree, salivary
glands, periorbital tissues, kidney, lung, lymph node,
aorta, prostate, thyroid, and pericardium. IgG4-associ-
ated cholangitis (IAC) was introduced which refer to
the biliary manifestation of IgG4-RD. Since various
cholangiographic features of IAC are similar to those
of primary sclerosing cholangitis (PSC), pancreatic can-
cer, and cholangiocarcinoma (CCC), it is often difficult
to discriminate IAC from these progressive or malig-
nant diseases on the basis of cholangiographic findings
alone. Therefore, multidisciplinary approach is very
important in order to avoid the misdiagnosis of PSC
and malignant diseases.
Clinical features:
Demographics and clinical manifestation: The overall
IAC epidemiology remains largely undefined yet. In the
literature, men appear to be more commonly affected
IAC same as PSC however, patient’s age at clinical
onset is around two decades older in IAC than in PSC,
and no case of IAC have been reported in children con-
trary to PSC. Obstructive jaundice is the most common
clinical presentation in IAC which is rarely observed at
diagnosis in PSC. And also, other organ involvement
can often be found in IAC, IAC is especially common
associated with autoimmune pancreatitis (AIP).
Laboratory test: Level of alkaline phosphatase (ALP)
and serum bilirubin level tend to be higher in patients
with IAC in comparison with PSC. And also, a serum
IgG4 increase is characteristic of IAC. However, it may
not be diagnostic of the disease because some patients
with IAC did not have increased levels of IgG4 at the
time of diagnosis. And high level of the tumor marker
CA 19-9 are common in patients with IAC therefore,
CA19-9 levels do not seen to help to distinguish
between IAC and CCC.
Cholangiography: Confluent stricture and prestenotic
dilatation is a characteristic feature of IAC. These chol-
angiographic findings are different from PSC which
shows band-like stricture, beaded appearance, pruned-
tree appearance, and diverticulum-like out pouching.
IAC associated with autoimmune pancreatitis (AIP)
frequently shows a structure of the distal common bile
duct. This stricture might be caused by both the thick-
ening of the bile duct and the effect of inflammation
and/or edema of the pancreas.
Histopathology: The histological appearances of IAC
are basically similar to those observed in other IgG4-
RD. The inflammation is typically transmural with a
massive lymphoplasmacytoid infiltration, and is at
times associated with moderate tissue eosinophilia. The
cellular infiltrates are evenly distributed throughout the
wall of the duct and peri ductal tissue. Obliterative
phlebitis and perineural inflammatory extension are
noted, especially the outer layer of the bile duct wall.
The inflammatory process is intermingled with a unique
storiform pattern of fibrosis as the inflammation pro-
gressed. However, the biliary lining epithelium is usu-
ally intact, despite the dense per luminal inflammation.
This is contrast to PSC, which often involves luminal
side and lining epithelium of bile ducts and produces
erosion. And also, neutrophils are commonly seen
rather than lymphocyte or plasma cell in PSC. On
immunohistochemistry, IgG4 antibodies mark many
plasma cells, and these cells are diffusely distributed in
the inflamed area. A recently published consensus doc-
ument proposed that >100 IgG4-positive plasma cells
per high-power field (HPF) in surgical specimens and
>10/HPF in biopsy samples are required for diagnosis
of positive IgG4 immunohistochemistry.
Diagnosis: Many patients who have turned out to have
IAC have only been diagnosed after a major surgical
resection because it is difficult to diagnosis without
careful consideration. If surgery is needed, it is required
major surgery which has high morbidity and mortality
because of anatomic localization. Therefore, accurate
diagnosis is very important, for this reason, many stud-
ies proposed several diagnostic approaches. There have
been published two diagnostic criteria. All of them
include clinical feature, imaging, serology, histology,
other organ involvement, and response to steroid ther-
apy as important markers for IAC diagnosis.
Treatment: Corticosteroid is a treatment of choice for
IAC. However, there are few data on what the dura-
tion of treatment of IAC should be. In the recent con-
sensus, typical protocol is to treat with 40 mg/day of
prednisone for 4 weeks and then, evaluate steroid
response such as biliary stricture, biochemical abnor-
mality, serum IgG4 level and CA 19-9. If there is good
response for steroid, patients are followed by a 5-mg/
week taper for a total of 11 weeks on treatment.2 If
there is suboptimal response, additional procedure like
biliary stent insertion or surgical correction are consid-
ered. When the disease is recurred, it can be treated
with immunomodulatory drug combination as well as
steroid.2,3,10 There is careful to comment prognosis of
IAC because there have not been sufficient data about
natural history and long term follow-up. However,
there has been no one who develops cholangiocarcino-
ma or needs liver transplantation due to progressed
liver cirrhosis in patients with adequate treatment.
Among patients who are not undergone any treatment
for IAC, someone needed liver transplantation because
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of liver failure. However, we think that liver failure
might be caused by prolonged jaundice rather than
IAC progression.
Up05
WHAT IS THE LIMIT OF LIVER
RESECTION FOR COLORECTAL LIVER
METASTASIS?
Jean-nicolas Vauthey
MD Anderson Cancer Center, USA
Recent advances in chemotherapy and surgical manage-
ment have contributed to a marked increase in the
number patients who may be candidate for curative
resection of colorectal liver metastases (CLM). Patients
with advanced CLM formerly considered unresectable,
can now undergo curative liver resection using sequen-
tial multidisciplinary approaches. In this lecture, we
will review the recent strategies to evaluate and increase
the resectability of CLM, and provide an overview of
the surgical outcomes of liver resection for CLM based
on the latest evidence.
Evaluation of resectability: Pre-treatment imaging is
essential for diagnosis, staging, treatment planning, and
evaluation of response to chemotherapy. The eligibility
for resection in patients with CLM is determined by
two factors: oncological benefit and technical feasibil-
ity. From an oncological standpoint, complete resection
of all viable disease is crucial to expect survival benefit
from surgery. In adequately selected patients, presence
of extrahepatic disease does not represent an absolute
contraindication for surgery. Response to preoperative
chemotherapy is pivotal in the evaluation the oncologi-
cal resectability. Development of new lesions during
administration of preoperative chemotherapy is associ-
ated with poor prognosis after surgery. However,
growth of pre-existing intrahepatic lesions itself does
not predict poor outcome. Therefore, patients showing
this pattern of progression should remain candidates
for surgery as long as radical resection is technically
feasible. Technical resectability is based on adequate
knowledge of liver anatomy, histopathology, and liver
function. When major resection is considered, the func-
tional reserve of the liver should be estimated using
both static and dynamic measurements. The most reli-
able static variable is the standardized future liver rem-
nant (sFLR) volume which strongly correlates with
postoperative morbidity and mortality. The sFLR is
calculated by dividing the absolute future liver remnant
volume derived from computed tomography by the
total liver volume derived from a formula based on
body surface area. Minimal requirements of sFLR has
currently been set at >20% in normal liver, >30% in
damaged liver after extensive treatment, and >40% in
cirrhotic liver. For the patients who receive more than
3 months of systemic therapy, the required sFLR is at
least 30% to prevent postoperative hepatic insuffi-
ciency. In addition, dynamic measurements of the liver
volumes such as degree of hypertrophy (DH) and
kinetic growth rate (KGR) after portal vein emboliza-
tion (PVE) have also been reported to be more sensitive
predictors of functional reserve of the liver in patients
undergoing extended hepatectomy.
Strategies to increase resectability: Portal vein emboli-
zation (PVE) is a safe, minimally invasive procedure
which leads to atrophy of the liver to be resected and
compensatory hypertrophy of the FLR. To maximize
the regeneration of the FLR, optimal selection of
embolic materials and concurrent embolization of seg-
ment IV portal vein have been recommended. Two-
stage liver resection (TSR) is a modern surgical strategy
for extensive bilateral CLM that cannot be resected by
conventional single-stage hepatectomy. TSR is indi-
cated to patients in whom first-stage limited resection
can clear the less affected side of the liver before a
major – often extended contralateral hepatectomy.
Completion of TSR offers favorable prognosis with
reported 5 year survival rates of up to 64%. In patients
with synchronous primary tumor and CLM, the two
options for staged surgery are the ‘classic approach’,
which is resection of the primary tumor first, and the
‘reverse approach’, which is resection of the CLM first.
The fact that the combined approach could increase
the surgical risk for some patients is supported by a
large multi-institutional analysis that demonstrated a
more than threefold increase in morbidity and mortal-
ity for simultaneous colorectal and liver resection com-
pared with major hepatectomy alone. Such
complications will negatively impact on the well-defined
sequence of chemotherapy and surgery for patients
with stage IV disease.
Short-term surgical outcomes: The main cause of mor-
tality related to liver resection is hepatic failure
(18.4%), followed by hemorrhage (17.5%) and sepsis
(16.5%). Although the definition of liver failure varied
among institutions, a review of 1059 noncirrhotic
patients undergoing major hepatectomy demonstrated
that peak serum bilirubin level of >7.0 mg/dL was a
potent predictor of major complication (OR 10.0) and
90-day mortality (OR 10.8). A clear definition of hepa-
tic insufficiency optimizes the evaluation of minimal
requirement of FLR volume based on the background
liver status, and this has also contributed to develop
advanced concept of dynamic measurement of liver vol-
ume such as degree of hypertrophy or kinetic growth
rate after PVE.
Long-term outcomes and prognostic factors: With the
refinements in surgical procedures and multidisciplinary
approaches, the 5-year survival rate after curative resec-
tion of CLM has been reported to be up to 58%. Con-
ventional prognostic factors of outcome such as tumor
size, tumor number, and carcinoembryonic antigen
level are increasingly replaced by more powerful predic-
tors based on tumor biology such as response to preop-
erative chemotherapy and somatic mutational status.
(1) Pathologic response: pathologic response to preop-
erative chemotherapy stratifies both overall and recur-
rence-free survival of patients undergoing liver
resection for CLM. However, the limitation in clinical
settings is that the pathologic response is difficult to
assess prior to surgery. (2) Radiologic response: the
conventional size-based assessment according to the
Response Evaluation Criteria in Solid Tumors may
underestimate the response to chemotherapy. To over-
come this issue, our group first reported that changes
consisting in a ‘cystic-like’ alteration in the texture of
tumor on CT image (optimal morphologic response)
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can be used as alternative criteria for evaluating radio-
logic response to chemotherapy. A recent study demon-
strated that a suboptimal morphologic response is a
strong ‘preoperative’ predictor of worse overall and
recurrence-free survival. (3) Somatic mutational status:
During the past decade, the study of somatic gene
mutations has become a focus of colorectal cancer
research. Recent studies demonstrated that RAS muta-
tion is a predictor of worse survival in patients under-
going resection of CLM. The results indicate that RAS
mutation is a strong marker of oncological aggressive-
ness after resection of CLM. The finding of a non-
mutated tumor status (wild-type RAS status) encour-
ages us to pursue more aggressive treatments in high
risk patients or in patients whose disease is considered
borderline resectable based on tumor extent intrahepat-
ically and/or extrahepatically.
Up06
CURRENT STATUS AND FUTURE
PERSPECTIVES OF ROBOT IN HBP
SURGERY
Herbert John Zeh
University of Pittsburgh, USA
An established body of literature now supports the
safety and feasibility of minimally invasive pancreas
resections; more recent reports suggest an advantage
over the traditional open approach. Fueled by these
reports and the realization that the robotic platforms’
stereotactic imaging and enhanced instrument dexterity
are superior to laparoscopy; data is now emerging sug-
gesting an advantage to the use of robotics in pancre-
atic surgery. Several studies have now demonstrated
that the robotic platform is superior to open and lapa-
roscopic approaches for the distal pancreatectomy;
including decreased conversion rates, decreased blood
loss and ability to perform a better oncologic resection.
Similar advantages can be expected for the more com-
plex pancreaticoduodenctomy as experience matures. In
addition it appears that the robotic platform is more
versatile and easily mastered by new adopters of the
technology. We review here data supporting the use of
the robotic approach to complex pancreatic surgery
and demonstrate specific examples the robotic platform
offers advantages over open and laparoscopic tech-
niques.
Up07
RECENT ADVANCE IN THE IMAGING
DIAGNOSIS OF HCC
Jeong Min Lee
Seoul National University Hospital, Korea
With the recent dramatic advances in diagnostic modal-
ities, the diagnosis of hepatocellular carcinoma (HCC)
is primarily based on imaging. Ultrasound (US) plays a
crucial role in HCC surveillance. Dynamic multiphasic
multidetector-row CT (MDCT) and magnetic reso-
nance imaging (MRI) are the standard diagnostic meth-
ods for the noninvasive diagnosis of HCC, which can
be made based on hemodynamic features (arterial
enhancement and delayed washout). The technical
development of MDCT and MRI has made possible
the fast scanning with better image quality and resolu-
tion, which enables an accurate hemodynamic evalua-
tion of hepatocellular tumor of dynamic CT as well as
an application of perfusion CT and MRI into clinical
practice. Perfusion CT and MRI can measure perfusion
parameters of tumor quantitatively and can be used for
treatment response assessment to anti-vascular agents.
Besides the information of hemodynamic or perfusion
features of HCC, new advances in MRI can provide a
cellular information of HCC. Liver-specific hepatobilia-
ry contrast agents, such as gadoxetic acid, gives infor-
mation of hepatocellular function or defect of the
lesion, which improves lesion detection and character-
ization. Diffusion-weighted imaging (DWI) of the liver
also gives cellular information of HCC and has broad-
ening its role such as lesion detection, lesion character-
ization and treatment response assessment to
chemotherapeutic agents. In this article, we provide an
overview of the state-of-the art imaging techniques of
the liver and their clinical role in management of HCC.
Up08
UPDATES- INTERNATIONAL
CONSENSUS GUIDELINES 2012 FOR
MANAGEMENT OF IPMN
Masao Tanaka
Kyushu University, Japan
After 6 years of accumulation of evidences, the IAP
consensus guidelines for the management of IPMN and
MCN of the pancreas have been revised in 2012. My
talk will focus on the major changes of the guidelines
on the IPMN side, not on the MCN side. The macro-
scopic morphological classification into three types, i.e.,
main duct (MD), branch duct (BD) and mixed, has not
been changed, although the classification is granted as
more radiological than histological due to the increased
number and importance of nonoperative management.
The only change in the classification is the lowered
threshold of main pancreatic duct (MPD) from 10 mm
to 5 mm for the diagnosis of MD-IPMN to increase
the sensitivity of the diagnosis of MD-IPMN. To pre-
dict malignancy, high-risk stigmata are defined again,
but only to include jaundice, contrast enhanced solid
component, the size of MPD >10 mm, of which the
presence of solid components or mural nodules is the
most reliable. The size of BD-IPMN >30 mm was
included in the high-risk stigmata in the Sendai guide-
lines but notorious to decrease the specificity. The
revised Fukuoka guidelines have made a different cate-
gory of ‘worrisome features’, and the cyst size >30 mm
has been moved to this category. The other worrisome
features include thickened and enhanced cyst wall,
MPD 5–9 mm, mural nodules without enhance- ment,
MPD stricture with upstream dilation, and lymphade-
nopathy. All BD-IPMNs with these worrisome features
should be further evaluated by EUS. If no ‘worrisome
features’ are present, no further initial work-up is rec-
ommended, although surveillance is still needed. Histo-
logical aspects include a change in the definition of
‘malignancy’ of IPMNs byabandoning the term ‘carci-
noma in situ’ in favor of high-grade dysplasia (HGD),
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reserving the descriptor of malignancy for invasive car-
cinoma according to the recent WHO classification.
Also, instead of ‘minimally invasive carcinoma’, staging
invasive carcinomas with the conventional staging pro-
tocols and further substage the T1 category into T1a
(0.5 cm), T1b (0.5–1 cm), and T1c (1–2 cm) is recom-
mended to make accumulation of data and interinstitu-
tional comparison possible. The histologic subtypes of
IPMN have clinicopathologic significance and are
adopted in the Fukuoka Guidelines. The gastric type is
typically low grade, with only a small percentage devel-
oping into carcinoma, but if a carcinoma develops, it is
usually of the tubular type and aggressive. Large intes-
tinal-type IPMNs can have invasive carcinoma of the
colloid type with indolent behavior. Rather rare onco-
cytic type forms a large noninvasive tumor and then
tends to be misdiagnosed as MCN. Most infrequent
pancreatobiliary type has a high malignant potential
and shows aggressive behavior after malignant transfor-
mation. Gastric type is frequent in BD-IPMN and
intestinal type is frequently of MD type. Whenever
IPMN is resected, frozen section analysis of the pancre-
atic margin is mandatory. If the margin is positive for
HGD, additional resection should be attempted to
obtain at least intermediate-grade dysplasia. All
patients should be informed about the possibility of
total pancreatectomy. Distinction between carcinoma
derived from IPMN and carcinoma concomitant with
IPMN is proposed with regard to the topological rela-
tionship and histological transition, although the dis-
tinction sometimes remains undetermined. Resection is
recommended in all surgically fit patients with MD-
IPMN. The indications for resection of BD-IPMN have
become more conservative. BD-IPMN larger than 3 cm
without ‘high-risk stigmata’ can be observed without
immediate resection, particularly in elderly patients.
Pancreatectomy with lymph node dissection remains
the standard for invasive and non-invasive IPMNs.
Focal nonanatomic resection or anatomic resection
without lymph node dissection or splenectomy may be
considered for those without suspicion of malignancy,
but carry a risk of possible leakage of mucin, and
higher incidences of pancreatic fistula and recurrence.
As multifocal BD-IPMNs carry a similar risk of malig-
nancy to unifocal BD-IPMN, segmental resection can
be performed to remove IPMNs at the highest oncolog-
ical risk. The threshold for TP should perhaps be low-
ered in patients with a strong family history of PDAC
and multifocal BD-IPMNs, but the data supporting
this idea are incomplete.
Synchronous or metachronous combination of pancre-
atic cancer and benign IPMN, and the development of
a new carcinoma in the pancreas remaining after resec-
tion of IPMN is recent concerns in the management of
IPMN. In our series, the prevalence of ductal adeno-
carcinoma is 9.2% in total, and 10.8% if confined to
those with BD-IPMN. Others also reported this phe-
nomenon in 2.0–9.2% of patients with BD-IPMN. On
the other hand, the incidence of the carcinoma develop-
ment has been shown to be around 1% per year. All
BD-IPMNs need periodical surveillance at least twice a
year by either EUS, CT, or MR to check their malig-
nant transformation and development of distinct ductal
carcinoma during observation and even after resection
of BD-IPMN with surgical indication. The best modal-
ity and interval for surveillance remain to be deter-
mined. The new guidelines highlight a variety of issues
that remain controversial and areas where further
research is required.
Up09-1
HOW TO DIAGNOSE AIP?
Myung-Hwan Kim
Asan Medical Center, Ulsan University, Korea
The diagnosis of autoimmune pancreatitis (AIP)
remains challenging. Several sets of diagnostic criteria
for AIP have been advocated around the world, includ-
ing the JPS criteria (2002, 2006 and 2011), the HISORt
criteria (2006 and 2009), the Korean criteria (2007), the
Asian diagnostic criteria (2008) and the International
Consensus Diagnostic Criteria (ICDC, 2010). Diversity
of diagnostic criteria for AIP in each country may
reflect differences in practice patterns in the usage of
various tests, local expertise and clinical epidemiology.
The ICDC for AIP have been recently proposed by
Eastern and Western experts because of the need to
diagnose AIP regardless of practice patterns in the
usage of various tests and to incorporate differentiation
of the two subtypes of AIP. The ICDC use the combi-
nation of five cardinal features of AIP; pancreatic
imaging (parenchyma and duct), serology, other organ
involvement (OOI), histology and steroid responsive-
ness. The ICDC feature a grading of each category
depending on diagnostic reliability, and the criteria for
type 1 AIP and type 2 AIP were developed separately.
The diagnosis of type 1 AIP and type 2 AIP can be
definitive or probable, and in some cases, the distinc-
tion between the subtypes may not be possible (AIP–
not otherwise specified). Pancreatic findings on abdomi-
nal CT or MRI are often the first clue that raises the
suspicion of AIP. The typical imaging finding on
abdominal CT is diffuse enlargement of pancreas with
delayed enhancement, sometimes associated with rim-
like enhancement. In 30–40% of cases of AIP, indeter-
minate imaging findings including segmental/focal
enlargement of pancreas and atypical imaging (low-
density mass, pancreatic ductal dilatation, distal atro-
phy) are found, which make the distinction from pan-
creatic cancer difficult. The key findings of endoscopic
retrograde pancreatography (ERP) highly suggestive of
AIP include; (i) a long stricture involving more than 1/
3 of the duct length, (ii) lack of upstream duct dilata-
tion from the stricture, and (iii) multifocal strictures. In
the ICDC, the performance of diagnostic ERP is not
mandatory and pancreatographic findings assume the
role of collateral evidence when CT features are not
typical or in seronegative patients without OOI. Type 1
AIP is associated with a variety of serological abnor-
malities, among them, the single best marker of AIP is
elevated serum level of IgG4 (>135 mg/dL). Serum
IgG4 levels >2 times upper limit of normal are highly
specific for AIP. Serologic criterion of the ICDC does
not rely on total serum IgG level or autoantibodies
because of their low specificities. In type 2 AIP, eleva-
tion in serum IgG4 is uncommon. Although type 1
AIP as pancreatic manifestation of IgG4-related disease
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can involve virtually every organ system throughout
the body, the ICDC restrict the radiologic/physical evi-
dence of OOI only to proximal bile duct stricture, ret-
roperitoneal fibrosis, symmetrically enlarged salivary
glands, and renal involvement. That’s because the
imaging features of other extrapancreatic organ
involvement (e.g., lymph node, lung) may generally
nonspecific and do not permit reliable distinction
between AIP and pancreatic cancer. In type 1 AIP, the
pancreatic histology demonstrates a classical pattern
known as lymphoplasmacytic sclerosing pancreatitis
(LPSP); (i) periductal lymphoplasmacytic infiltrate
without granulocytic infiltration, (ii) obliterative phlebi-
tis, (iii) storiform fibrosis, and (iv) abundant IgG4(+)
cells. In type 2 AIP, the affected pancreas demonstrates
neutrophilic infiltration in the ductal epithelium with
duct destruction and occasionally microabscess forma-
tion, which is characterized by granulocytic epithelial
lesion (GEL). Type 1 AIP often can be diagnosed with-
out histology, but, in type 2 AIP, diagnosis can only be
made definitely by histological findings. EUS-guided
pancreatic core biopsy may play a bigger role in the
diagnosis of AIP. Especially, newly developed core
biopsy needles with enhanced flexibility and improved
tissue acquisition can access all areas in the pancreas.
This may attain two goals of histologic examination in
one sitting with the use of the same needle; exclusion of
pancreatic cancer and histologic diagnosis of AIP. A
steroid trial to diagnose AIP involves use of predniso-
lone with reassessment of imaging after 2 weeks of ste-
roid trial. Patients with indeterminate CT features
should first be investigated for pancreatic cancer and
steroid trial should be considered only if work-up for
cancer including EUS-FNA is negative. A diagnostic
trial of steroid therapy should not be used as a substi-
tution for efforts to exclude malignancy. If the response
to steroids is negative or equivocal, surgical exploration
should be conducted. As our understanding of the
manifestations and complete spectrum of AIP increase,
the diagnostic criteria for AIP are still evolving. There
is a need for a clear consensus on several issues and
prospective validation for the diagnostic criteria.
Up09-2
CUTTING EDGE CONCEPTS OF
AUTOIMMUNE PANCREATITIS (AIP)
Shefali Agrawal
Indraprastha Apollo Hospitals, India
Pancreatic and biliary manifestations of AIP mimic
pancreatico-biliary cancers. Misdiagnosis of AIP can
result in major surgery for a steroid-responsive disease.
A review of the diagnostic strategies used to distinguish
AIP from pancreatico-biliary cancers to minimize oper-
ative intervention for an autoimmune disease. Diagnos-
tic criteria for AIP are based on histology, imaging,
serology, extrapancreatic organ involvement and
response to steroid therapy (HISORt). The most com-
monly involved extrapancreatic sites are bile duct, kid-
ney and retroperitoneum. The Mayo Clinic diagnostic
strategy utilizes core biopsy of the pancreas and the
Japanese strategy depends on a characteristic pancrea-
togram. The rate of operative intervention was similar
with both strategies and none of the patients with can-
cer received steroid therapy. IgG4-associated cholangi-
tis mimics cholangiocarcinoma and presence of >10
IgG4-positive plasma cells/HPF on endoscopic biopsy
of the bile duct was diagnostic for AIP in 88%
patients. Biliary complications and early relapse are
common after surgical resection and immunomodula-
tory drugs can maintain long-term remission. Criteria
based on histology, imaging, endoscopy, serology, ex-
trapancreatic organ involvement and response to ste-
roid therapy improve the diagnostic yield for AIP.
Application of diagnostic and therapeutic protocols by
a multidisciplinary team will optimize outcomes with a
decline in the rate of operative intervention for misdi-
agnosis of AIP a steroid-responsive disease with pro-
pensity for relapse.
Up11
HOW TO PREVENT LIVER FAILURE
AFTER HEPATECTOMY
Sheung Tat Fan
The University of Hong Kong, China
Liver failure, defined as the inability of the liver to
maintain its synthetic, excretory and detoxifying func-
tions on or after postoperative day 5, remains to be the
most dreadful complication after hepatectomy. To pre-
vent liver failure after hepatectomy, careful preopera-
tive liver function assessment and remnant liver volume
measurement are mandatory. The minimum remnant
liver volume for postoperative patient survival is about
20%, 30% and 40% for normal livers, livers with
chronic hepatitis and livers with mild cirrhosis, respec-
tively. Intra-operatively, strategies must be exercised to
maintain venous return of the liver remnant and to
avoid sacrifice of the uninvolved liver, hypoxic or ische-
mic change to the liver remnant, massive bleeding and
liver necrosis. Bile leakage and bile duct damage must
also be avoided and checked for thoroughly before clo-
sure of the abdomen. Postoperatively, adequate pain
control, fluid replacement and nutritional support will
expedite recovery. Liver failure is signified by low
blood pressure and oliguria despite massive fluid load-
ing. Prompt renal replacement therapy and use of ino-
tropes may halt further deterioration. With careful
preparation and meticulous perioperative care, the risk
of liver failure after hepatectomy can be reduced to
almost 0%. Liver failure after hepatectomy is prevent-
able.
Up12
INDICATIONS AND OUTCOME OF
SURGERY FOR ACUTE NECROTIZING
PANCREATITIS
Rowan W Parks
University of Edinburgh, UK
Introduction: Acute pancreatitis is defined as an acute
inflammatory process of the pancreas, with variable
involvement of other organ systems. In approximately
85% of patients, acute pancreatitis is a rapidly-resolv-
ing condition requiring little more than analgesia and a
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short period of intravenous fluid resuscitation. How-
ever, for the remaining 15% who develop a multi-sys-
tem illness, characterised by a systemic inflammatory
response and a variable degree of organ dysfunction,
the mortality rate may be as high as 40%.
Several important issues regarding the optimal manage-
ment of patients with severe necrotising pancreatitis
have been the subject of continuing debate. These
include the indications and timing for intervention and
the type of procedure undertaken. Historically, open
surgical debridement was the mainstay of intervention
for patients deemed to have infected necrotising pancre-
atitis. However, recent advances, including the develop-
ment of radiological, endoscopic and various minimally
invasive surgical approaches, has increased the arma-
mentarium available to the clinician with responsibility
for managing these complex and often challenging
patients.
Numerous reviews and guidelines on the management
of patients with acute pancreatitis have been published
over the years. The most recent comprehensive evi-
dence-based guidelines were published by the IAP/APA
Working Group in 2013 (1).
Indications for Intervention in Necrotising Pancreatitis:
Recognised indications for intervention are: (i) Clinical
suspicion of, or documented infected necrotising pan-
creatitis with clinical deterioration, preferably when the
necrosis has become walled-off, (ii) Ongoing organ fail-
ure for several weeks after the onset of acute pancreati-
tis in the absence of infected necrosis, preferably when
the necrosis has become walled-off.
Routine percutaneous fine needle aspiration (FNA) of
peripancreatic collections to detect bacteria is not indi-
cated, because clinical signs (ie persistent fever, increas-
ing inflammatory markers) and imaging signs (i.e., gas
in the peripancreatic collections) are accurate predictors
of infected necrosis, and FNA may result in a false
negative result.
Indications for intervention in patients with sterile nec-
rotising pancreatitis are: (i) Ongoing gastric outlet,
intestinal or biliary obstruction due to mass effect of
walled-off necrosis, (ii) Persistent symptoms in patients
with walled-off necrosis.
Timing of Intervention in Necrotising Pancreatitis: A
number of studies have suggested that early interven-
tion is more difficult and associated with a higher mor-
tality than delayed intervention. There has only been
one randomised trial comparing early and late interven-
tion and this had to be terminated because of the sig-
nificantly higher mortality rate in the early group.
Therefore, for patients with proven or suspected
infected pancreatic necrosis, invasive intervention
should be delayed where possible until at least 4 weeks
after initial presentation to allow the collection to
become walled-off.
Intervention Strategies in Necrotising Pancreatitis: The
optimal interventional strategy for patients with
suspected or proven infected necrotising pancreatitis is
initial image-guided retroperitoneal percutaneous cathe-
ter drainage or endoscopic transluminal drainage,
followed, if necessary by surgical or endoscopic necro-
sectomy.
Percutaneous catheter drainage alone will resolve 25–
50% of cases without any requirement for additional
surgical intervention. A multicentre RCT in 88 patients
with (suspected) infected necrotising pancreatitis
showed that a step-up approach of percutaneous retro-
peritoneal catheter drainage, followed by minimally
invasive necrosectomy decreased major short-term com-
plications such as new onset multi-organ failure, and
long-term complications such as endocrine insuffi-
ciency, and decreased costs compared to primary open
surgery (2). If percutaneous catheter drainage fails, the
optimal form of intervention (minimally invasive sur-
gery, open surgery or endoscopic necrosectomy) is not
defined and will depend on local expertise and experi-
ence.
Outcome of interventions in Necrotising Pancreatitis:
The reported mortality after pancreatic necrosectomy
in cohort studies after necrosectomy varies widely from
0% to 40%. This may be related to variations in case-
mix, indications for, or timing of intervention between
centres, however to date no clear explanation has been
determined.
Long-term morbidity is rarely reported, but remains
high, with surviving patients often suffering from either
endocrine or exocrine pancreatic insufficiency.
Conclusion: The management algorithm for patients
with necrotising pancreatitis has altered radically in the
past two decades in response to evolving concepts,
improved understanding and the development of mini-
mally invasive techniques, including percutaneous and
endoscopic necrosectomy as an alternative to conven-
tional open debridement. A multi-disciplinary approach
has evolved and it is not uncommon for several tech-
niques to be utilised in an individual patient, as the
indication and clinical condition of the patient alter
during the course of the disease process. Efforts to
reduce mortality should focus on intensive multi-disci-
plinary supportive measures to optimise organ function
so that intervention can be delayed. The guiding princi-
ple for intervention is now on the ‘adequate and main-
tained control of sepsis’.
References:
1. IAP/APA evidence-based guidelines for the manage-
ment of acute pancreatitis. Pancreatology 2013; 13:
e1–e15.
2.Van Santvoort HC et al. A step-up approach or open
necrosectomy for necrotising pancreatitis. N Eng J
Med 2010; 362: 1491–1502.
Up13
BEST STRATEGY FOR THE
MANAGEMENT OF INTRAHEPATIC
CHOLANGIOCARCINOMA
Richard Schulick
University of Colorado School of Medicine, USA
Intrahepatic cholangiocarcinoma (ICC) is the least
common type of cholangiocarcinoma when compared
to perilla and distal subtypes. Over the last several dec-
ades the incidence of intrahepatic cholangiocarcinoma
appears to be increasing. Unlike the peri hilar and dis-
tal subtypes, patients do not typically present with
obstructive jaundice and are more likely to present with
larger masses and abdominal pain. Tumor markers
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such as CEA and CA 19-9 are sometimes elevated, but
normal levels do not rule out ICC. This talk will focus
on the results of multiple single, as well as multi-insti-
tution series reporting on the treatment of ICC. Surgi-
cal resection remains the mainstay of curative intent
therapy when it is possible. In multiple series reported
over the last two decades, the median survival after
resection of patients ranges between 12 and 37 months
with 5-year survival rates ranging between 22 and 57%.
Many times these resections can be accomplished via
hepatectomies such as segmentectomies, bisegmentecto-
mies, hemihepatectomies, and extended hepatectomies.
The bulkier lesions, especially those that grow towards
the hilus may require biliary reconstruction to the con-
tralateral side or even vascular reconstruction. Other
modalities to treat ICC include systemic chemotherapy,
and occasionally transarterial chemoembolization for
lesions with vascularity or radiofrequency ablation for
smaller lesions in patients unable to undergo surgical
resection. The role of liver transplantation of ICC
remains controversial, but those patients with very
small (<2 cm) lesions in the context of cirrhosis do as
well as those undergoing transplantation for HCC. The
standard practice for unresectable of advanced-staged
ICC is systemic chemotherapy with gemcitabine and
cisplatin for those patients who have good performance
status. Intrahepatic cholangiocarcinoma is a very rare
cancer and is much less common than the perihilar and
distal subtypes. Surgical resection, when possible
remains the most effective therapy.
Up14
BEST PREOPERATIVE PREPARATION
FOR MAJOR HPB SURGERY
ThomasVan Gulik
Academic Medical Center AMC Netherlands
The aim of an effective preoperative regimen in HPB
surgery is to reduce postoperative complications. As
with any ‘major’ surgery, general factors such as nutri-
tional state and cardiovascular function obviously need
to be optimalized preoperatively. Prophylactic antibi-
otic therapy is routinely administered to prevent infec-
tious complications. Specific preoperative measures are
directed to prevent typical complications after hepatob-
iliary surgery or pancreatic procedures. These are
addressed in the following.
Major HPB surgery grossly includes pancreatoduoden-
ectomy (PPPD or classical Whipple’s resection) for
pancreatic or periampullary tumors, liver resection (≥3
segments), and liver resections in combination with
resection of the extrahepatic bile ducts such as in resec-
tion for hilar cholangiocarcinoma.
Pancreatic surgery: The most common complications
after pancreatoduodenectomy include anastomotic leak-
age (4–25%), delayed gastric emptying (15–40%) and
delayed hemorrhage (2–4%). The latter occurs late
(>24h) after surgery and is usually associated with
intra-abdominal septic complications. There are no
effective preoperative measures to reduce postoperative
DGE except perhaps, for naso-gastric tube decompres-
sion in patients requiring pancreatoduodenectomy for
an obstructive, duodenal tumor.
Preoperative biliary drainage (PBD) in patients undergo-
ing pancreatoduodenectomy: We conducted a large
RCT in the Netherlands, in which patients scheduled
for pancreatoduodenectomy were randomized between
PBD and direct surgery. A higher rate of serious com-
plications was found in the drainage group, while mor-
tality and hospital stay did not differ between the
groups. Based on these findings, we concluded that
routine PBD increases the rate of complications and
should thus not be routinely performed. However, there
remains an indication for PBD, when early surgery is
not possible, due to logistics in terms of (local) referral
patterns, waiting lists, extended diagnostic workup with
laparoscopy (on indication), or scheduled neo-adjuvant
chemotherapy.
Leakage of the pancreatic anastomosis: The most seri-
ous, potentially lethal complication after pancreatic sur-
gery is leakage of the pancreatic anastomosis, especially
when the pancreas is soft. One can anticipate a soft
pancreas with a small duct in periampullary tumors
that do not obstruct the pancreatic duct. Somatostatin
or its synthetic analogues have been used to reduce
postoperative pancreatic fistula, although its efficacy
has been debated. A recent Cochrane meta-analysis
(2012) showed that somatostatin analogues reduced
perioperative complications but did not reduce periop-
erative mortality. Based on current available evidence,
the authors recommended the routine use of somato-
statin analogues in pancreatic surgery. We do not
advocate the routine use of somatostatin analogues but
start with octreotide the day before surgery in patients
in whom a soft pancreas is suspected, and continue
postoperatively for 6 days.
Hepato-biliary surgery: Two important issues in hep-
ato-biliary surgery are the preoperative need of biliary
drainage and preoperative assessment of liver function
and volume of the future remnant liver.
Preoperative biliary drainage (PBD) in patients undergo-
ing bile duct resection in combination with major liver
resection: While there is now evidence showing that
PBD for periampullary and pancreatic tumours should
not be routinely performed (see above), this is not the
case for the more proximal cholangiocarcinomas, i.e.
HCCA. An important difference between distal
tumours as compared with hilar tumours lies in the
need for an (extended) liver resection in most patients
with HCCA. Liver resections in jaundiced patients are
associated with significantly increased rates of mortality
and morbidity, resulting mainly from the development
of postoperative complications such as sepsis, bleeding,
and most importantly, liver failure. Preoperative biliary
drainage is therefore recommended in patients with
HCCA and may be achieved endoscopically (ERCP) or
percutaneously (PTBD).
Preoperative CT volumetry to calculate volume of the
future remnant liver: CT volumetry is currently the
standard method to determine whether a patient can
safely undergo liver resection. A liver resection can be
safely performed when FRL volume is larger than 25–
30% of total liver volume in case of normal liver
parenchyma. In patients with underlying liver disease
however, a margin of 40% is preferred. Liver volume
does not necessarily reflect liver function, especially in
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patients with a compromised liver. Therefore, it is
important to reliably assess hepatic function in addition
to CT volumetry, before undertaking extended liver
resection.
Preoperative assessment of liver function: Insufficient
liver function is the single, most important determinant
of outcome after major liver resection. Accurate preop-
erative assessment of future remnant liver function is
therefore important in selecting patients for major liver
resection. Dynamic quantitative liver function tests
such as the ICG test, galactose elimination capacity
and lidocaine clearance test measure the elimination
process of a substance that is cleared and/or metabo-
lized almost exclusively by the liver. They however,
only measure global liver function. Nuclear imaging
techniques (99mTc-galactosyl serum albumin scintigra-
phy and 99mTc-mebrofenin hepatobiliary scintigraphy)
have the advantage of measuring both total and future
remnant liver function.
Preoperative portal vein embolization: Portal vein
embolization (PVE) is an accepted method worldwide,
to preoperatively increase volume of the future remnant
liver. After occlusion of one side of the portal vein,
atrophy of the embolized liver segments occurs, while
at the same time, hypertrophy of the contralateral,
non-embolized liver is induced, resulting in an increase
in volume and function of the FRL preoperatively. A
drawback of preoperative PVE is accelerated growth of
tumor while micrometastases in the non-embolized
remnant liver may also develop or progress.
Conclusion: Efficient preoperative preparation reduces
specific postoperative complications in major hepatobil-
iary surgery and pancreatic procedures. In patients
requiring pancreatoduodenectomy , preoperative biliary
drainage increases the rate of complications and should
not be routinely performed. Current evidence suggests
the routine use of somatostatin analogues in pancreatic
surgery to prevent anastomotic leakage. Unlike in pan-
creatic head tumors , preoperative biliary drainage is
recommended in patients with proximal bile duct
tumors requiring extended liver resection. When vol-
ume or function of the future remnant liver falls short,
preoperative portal vein embolization is to be consid-
ered.
Up15
ENHANCED RECOVERY AFTER
SURGERY (ERAS) IN HPB DISEASE
Marielle Coolsen
MUMC+, Netherlands
Introduction: Liver and pancreatic resections are com-
plex surgical procedures, which can cause considerable
surgical stress and possible disruption of metabolic and
pulmonary function. Improved operative techniques
and insight into perioperative management has lowered
mortality after liver resection to its current level of 5%
but morbidity rates remain high, ranging between 30%
and 50%. In large series morbidity rates for pancreatic
resections can be as high as 40% to 60%. In order to
improve postoperative outcome it is now recommended
to centralize these major abdominal procedures in spe-
cialized, high-volume clinics. Because of this, mortality
rates for pancreaticoduodenectomy (PD), which is the
most common form of pancreatic resection, have
decreased from 9.8% to 5.1% in the Netherlands. Post-
operative length-of-stay (LOS) after PD varies from 14
to 20 days in different studies. In many hospitals cur-
rent perioperative care for liver and pancreatic surgery
is still conservative. Nasogastric tubes are left in place
for days after surgery with the patient either receiving
no food at all or only through a needle jejunostomy.
Even though this delivers artificial nutrients it is an
intervention that bypasses the cephalic-vagal digestive
reflex and appears to be associated with considerable
risk. Other conservative practices are late postoperative
mobilization and placement of drains at the end of the
surgical procedure. It has been shown that in liver sur-
gery the placement of abdominal drains is not effective
and may even increase the risk of intra-abdominal
infections. Similarly, in pancreatic surgery the use of
abdominal drains is supported by little evidence. In a
randomized controlled trial (RTC) comparing routine
drainage versus no drainage after pancreatic surgery,
the incidence of intra-abdominal collections of fistulas
turned out to be higher after drainage. Fasting from
midnight also remains common practice in elective
(liver and pancreatic) surgery even though this is not
supported by evidence. It has been shown that patients
should be allowed to drink clear fluids up to 2 hours
and ingest solid food up to 6 hours before surgery.
Enhanced Recovery after Surgery (ERAS) programs,
also referred to as fast track, clinical or critical pathway
programs, are multimodal, standardized care protocols
implemented for a specific surgical field. An ERAS pro-
gram addresses a variety of evidence-based periopera-
tive interventions and demands a multidisciplinary
approach in which surgeons, anesthesiologists, intensive
care staff, and nurses work together as a team. The
purpose of an ERAS program is to accelerate postoper-
ative recovery and shorten postoperative length of stay
(LOS) without increasing or even lowering morbidity
and readmission rates. ERAS programs have been suc-
cessfully implemented in colonic surgery and appear to
reduce the length of stay and complication rates with-
out compromising patient safety. The LAFA trial com-
pared open colonic resection with laparoscopic
resection using either an ERAS protocol or a standard
care protocol. This trial showed that laparoscopy com-
bined with an ERAS protocol resulted in the optimal
perioperative treatment of patients undergoing colonic
resections. Numerous other studies have been published
on the implementation of ERAS programmes in many
other surgical fields (e.g., musculoskeletal, breast, aor-
tic, bariatric, and prostate surgery). All of these studies
showed a decrease in LOS without increasing postoper-
ative morbidity or mortality. Apart from a reduction in
postoperative LOS the implementation of an ERAS
program may also reduce complication rates after liver
and pancreatic surgery. Concerns have been raised,
however, regarding the safety of ERAS programs for
these upper gastrointestinal (GI) procedures since they
are still associated with relatively high morbidity rates
and excite a considerable stress response. A nil-by-
mouth regimen is still widely practiced because of fear
for gastric distention and anastomotic leakage. Espe-
cially in PD, where complications as delayed gastric
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary Association HPB 2014, 16 (Suppl. 2), 38–44
46 Update
emptying (DGE) regularly occur, there is a reluctance
to allow volitional intake of normal food during the
immediate postoperative period. This reluctance, how-
ever, is not justified by evidence obtained from ran-
domized trials and may even be considered ‘obsolete’
care. Even so, liver and pancreatic procedures are rela-
tively infrequent procedures for which it may be diffi-
cult to implement an ERAS program that requires
close collaboration between all caregivers. Anesthesiol-
ogists in particular must be willing to cooperate and
apply all perioperative ERAS components. This
includes allowing oral carbohydrate loading up to
2 hours before surgery, epidural anesthesia and the
removal of nasogastric tubes directly after surgery.
Given the success of ERAS programs in colonic sur-
gery as well as in many other surgical areas and the
abundant evidence for the individual elements of the
ERAS protocol one might hypothesize it should be
possible to implement an ERAS program for liver and
pancreatic surgery as well. Reducing the surgical stress
response, thereby enhancing recovery, might even lower
procedure-related morbidity. The reluctance to aban-
don conservative care surrounding HPB surgery should
be overcome thereby allowing room for the practice of
evidence-based care. This lecture covers the develop-
ment and implementation of ERAS programs in HPB
surgery and gives an overview of the most recent evi-
dence and outcomes
Up16
EUS GUIDED TRANSMURAL GB
DRAINAGE
Sang Soo Lee
Asan Medical Center, Ulsan University, Korea
Acute cholecystitis is one of the most common surgical
emergencies. Laparoscpic cholecystitis is the treatment
of choice with low procedure related complications.
However, the mortality rate cannot be ignored in high
risk patients. Traditionally this kind of patients under-
goes nonsurgical therapy such as medical treatment or
percutaneous transhepatic gallbladder drainage
(PTGBD) when the acute cholecystitis does not
respond medical therapy. Although technical success
and clinical response rate of PTGBD is nearly 100%,
complication rate has been reported up to 12%. The
complications are bile peritonitis, bleeding, peumotho-
rax, tube removal, and migration. In addition, PTGBD
might inappropriate for patients with massive ascites or
coagulopathy, and patient discomfort and cosmetic dis-
figurement have been associated with the drainage cath-
eter itself. Furthermore, catheter dislodgement has been
associated with repeat procedures. Endoscopic Gall-
bladder drainage is another alternative method. These
methods may overcome the limitation of PTGBD.
Endoscopic methods include transpapillary approach
which has been used more than 20 years, and EUS-
guided transmural approach which is attempted lately.
The technical success rate of endoscopic transpaillary
gallbladder drainage has been reported from 70% to
89% and clinical success rate reported 64–100%. The
limitation of this procedure is the lower success rate
compared with that of PTGBD. This low success rate
arises from cystic duct configuration, stricture or
obstruction by inflammation. EUS-guided gallbladder
drainage (EUS-GBD) might be an effective alternative
option such as PTGBD for the high-risk patients with
acute cholecystitis. The technical success rate and safety
of EUS-GBD is comparable to those of PTGBD.
Recently several types of special designed metallic
stents have been used in clinical field. In conclusion,
EUS-GBD has excellent potential as an alternative gall-
bladder decompression procedure. However, because
the current outcomes are limited, multicenter trials for
the precise evaluation of this procedure appear to be a
necessity in the near future.
Up17
LIVER TRANSPLANTATION FOR
METASTATIC MALIGNANCIES
Jan Lerut
University Hospitals Saint Luc UCL, Belgium
Aksel Foss, Yves Patrice, Le Treut, Linda Sher and
Rene Adam Due to improved surgical, peri-operative
and especially immunosuppressive care, liver transplan-
tation (LT) is nowadyas accepted as a valid therapy in
the field of hepatobiliary oncology.
Since LT is able to cure patients harbouring primary -
hepatocellular, vascular and even some cholangiocellu-
lar -liver tumors, interest was again raised in relation
to the place of LT in the treatment of secondary liver
tumors. It becomes now clear that LT might also gain
a definite place in the treatment of well selected neuro-
endocrine and even colorectal liver metastases. Based
on own experience, data from the ELTR and UNOS
registries and the available literature an overview will e
given about the actual status of LT in the field of
neuro-endocrine (NET) and colorectal liver metastases
(CRLM).
NET metastatic disease: Especially the Milan (Mazza-
ferro) and European ELTR (Le Treut) studies clearly
showed that outcome can be substantially improved
when sticking to well defined criteria such as previous
RO resection of the primary, response to medical ther-
apy,stable liver disease during 6 to 12 mo, level of
tumor activity as expressed by Ki 67 of 5 (to 10)%, age
(<55–60 years) ,tumor bulk (<50%) or hepatomagely
(>125% of standard liver volume), portal drainage of
the primary tumor and multistep surgery (avoiding
thereby mutiviscrel transplantation).
CRLMetastatic disease: The Norvegian SE (condary)
CA (ncer) study raised a lot of interests but also a lot
of concerns in relation to the use of scarce allografts
for this indication. The Oslo group however has the
great merit to have set up, in a well-defined scientific
and academic environment, a transplant program for
these particular patients. Although nearly all patients
recurred, their first experience with 21 patients permit-
ted to identify risk factors for tumor recurrence such as
hepatic tumor load before LT, time from primary CR
surgery to LT, progressive disease on chemotherapy
and level of CEA.
Lessons learned from these initial experiences will set
the stage for new projects to be started in a near future
in both fields of metastatic liver disease. LT might be a
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valuable therapy to cure some well selected patients
presenting with NET and CRL metastases. It is
expected that the encouraging, nowadays, obtained
results can be further improved by applying the sound
principles of oncology, nl adding neo-adjuvant and
adjuvant (target) therapies to the surgical procedure.
Up18
CURRENT EVIDENCE AND FUTURE
PERSPECTIVE OF MOLECULAR
TARGETED THERAPIES IN HCC
Masatoshi Kudo
Kinki University School of Medicine, Japan
Sorafenib was approved for the treatment of unrespect-
able hepatocellular carcinoma (HCC) in 2007 and is
the first molecular targeted agent to be used against
advanced HCC. To date, sorafenib remains the only
molecular targeted agent with a survival benefit which
has been demonstrated in two global phase III random-
ized controlled trials1,2, and it has since been approved
for use worldwide. To date, more than 10 phase III
global clinical trials of new molecular targeted agents
have been undertaken or are currently ongoing. Of
them, nine have failed to meet their primary endpoint
(as of Jan 2014). The trials are the Vitamin K2 adju-
vant study 3, the Japan–Korea post Transarterial
Chemoembolization (TACE) study 4, the Sunitinib first
line study 5, the Peretinoin (NIK333) adjuvant study6,
the Brivanib 2nd line study 7, the Brivanib 1st line
study, theBribanib/ TACE combination study, Linifa-
nib 1st line study, and the SEARCH (Sorafenib and
Erlotinib, a Randomized Trial Protocol for the Treat-
ment of Patients with HCC) study, which is a phase III
study of sorafenib in combination with erlotinib versus
sorafenib plus placebo. Problems experienced in the
Japan–Korea post TACE study may be related to study
design (sequential design), treatment lag after TACE
(9.3 weeks), and the high early discontinuation rate
(low drug exposure rate) 4. Problems with the Sunitinib
1st line trial may be due to high toxicity, low tolerabil-
ity, or the high dose reduction rate and drug discontin-
uation rate (low drug exposure rate) 5. The problem
with the Peretinoin adjuvant study after curative treat-
ment may be the result of the 300 mg dose of Peretino-
in failing to suppress the recurrence of HCC due to
poor pharmacological activity. Although, exploratory
subset analysis revealed a positive signal for the
600 mg dose of Peretinoin, showing a significant reduc-
tion of recurrence over the placebo 6. The problem of
the Brivanib 2nd line study could be the stage migra-
tion of sorafenib treatment to an earlier stage com-
pared with advanced stage assessments performed in
two initial phase III studies1, 2. In other words, sorafe-
nib was given for more intermediate stage HCC; there-
fore, even after 2nd line therapy, post-trial therapy
such as TACE or systemic/arterial infusion chemother-
apy might have been given to the 2nd line drug failure
patients. However, this study clearly demonstrated
improved anticancer efficacy, as measured by tumor
response rate and time to tumor progression. The prob-
lems with the Linifanib 1st line study, the Brivanib 1st
line study, and the SEARCH study remain unknown.
Details are expected to be presented at a forthcoming
scientific meeting. In conclusion, clinical trials using
new agents for the treatment of HCC in an adjuvant
setting, first line setting, second line setting, or TACE
combination setting seem to be experiencing difficulty
and yielding poor results. This failure might be attrib-
uted to any of the following reasons. First, HCC is
usually associated with impaired liver function or liver
cirrhosis; therefore, toxicity or intolerability may be
enhanced in relation to patients with normal liver func-
tion, resulting in early discontinuation or dose reduc-
tion. Second, aside from resection, there are many
effective treatment options for HCC such as ablation,
TACE8, and hepatic arterial infusion chemotherapy
(HAIC) 9. Therefore, post-trial treatment might have
affected the results of primary endpoints such as overall
survival. As the unmet needs for the treatment of HCC
remain in daily clinical practice, targeted agents are
needed to suppress recurrence after curative treatment
or TACE, and agents for advanced HCC in patients
with sorafenib resistance or intolerance are similarly
required. We look forward to positive results in ongoing
or newly emerging trials of agents that can overcome
the difficulties associated with HCC in cirrhotic liver.
Up20
REVISED TOKYO GUIDELINES 2013
Toshihiko Mayumi
University of Occupational and Environmental Health,
Japan
On the basis of the discussion at the International Con-
sensus Meeting (April 1–2, 2006), the diagnostic criteria
and severity assessment of acute cholangitis and chole-
cystitis were first published in the world as Tokyo
Guidelines (TG 07) in 2007. TG 07 were cited in many
English medical journals and disseminated immediately
after its publication, however, there was a divergence in
opinions from those working in clinical settings. Under
such circumstance, we formed a task force for updating
Tokyo guidelines 2007 (TG 07) and started the prepa-
ration of the revised diagnostic criteria and severity
assessment of acute cholangitis and cholecystitis. To
begin with, a total of 887 cases that agree with the gold
standard of cholangitis in choledocholithiasis/biliary
malignancy were collected with collaboration from mul-
tiple institutions. Diagnostic criteria and severity assess-
ment were then discussed. Similar discussions were also
conducted concerning acute cholecystitis. Major
changes in diagnostic criteria of cholangitis involved
exclusion of abdominal pain from the diagnostic items.
Regarding the severity assessment, ‘moderate’ acute
cholangitis is defined as being associated with any two
of the significant poor prognostic factors. Furthermore,
acute cholangitis that does not respond to the initial
medical treatment, which was classified as ‘moderate’ in
TG 2007, is now deleted. Therefore the sensitivity of
diagnostic criteria of TG 13 would improve from
82.8% (in TG 2007) to 90.8% in patients with choledo-
cholithiasis and from 84.1% (TG 2007) to 96.1% in
patients with malignancy. Specificity would also
improve from 45.9% (in TG 2007) to 93.4% in patients
with choledocholithiasis and from 65.6% (in TG 2007)
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to 75.0% in patients with malignancy. Severity assess-
ment could be carried out soon after the diagnosis of
acute cholangitis. Updated Tokyo guidelines (TG 13)
improved the diagnostic sensitivity and presented crite-
ria with extremely low false positive rates adapted for
clinical use. We hope TG 13 will become widely used
and be evaluated by many clinical studies.
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EXTENDING CURRENT INDICATIONS
OF LAPAROSCOPIC LIVER RESECTION
Ho-Seong Han
Seoul National University Bundang Hospital, Korea
Laparoscopic liver resection (LLR) is slowly regarded
as one of optional treatment for liver disease including
hepatocelluar carcinoma (HCC). However, there is still
limitation in applying this procedure .Especially, major
limitation on this procedure is the tumor location. The
current indication on location of the laparoscopic liver
resection is limited to easily accessible lesions. Until
now, most of reported cases have been limited to the
anterolateral segments (segments 2, 3, 4b, 5, 6). Per-
forming laparoscopic liver resection in the posterior
and superior parts of the liver has been considered
difficult due to inadequate exposure, the poor operative
field and the difficulty with parenchymal dissection.
However, there are several attempts that laparoscopic
liver resection was performed as open surgery in terms
of indications and operative methods. Flexible endos-
copy, high definition imaging and various kinds of
equipments for parenchymal transection have been
helpful for advanced technique. As the patients with
HCC have concomitant liver cirrhosis or chronic liver
disease, there is high probability of liver dysfunction
after liver resection. Therefore, it is necessary to per-
form organ sparing liver resection, so called tailored
approach for the patients with HCC. The type of resec-
tion also may depend on the remaining liver’s func-
tional capacity. Yet for safer laparoscopic liver
resection, the patient positioning and trocar placement
should be individualized according to the tumor’s loca-
tion. Tailored liver resection can be possible with the
use of Glissonian approach. For example, mono-seg-
mentectomy, the Glissonian pedicle to individual seg-
ment was isolated. In terms of challenging situation,
there are reports on the laparoscopic liver resection
when tumor is close to major vessels, hilum or inferior
vena cava. This procedure will be more advanced with
the accumulation of experiences.
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